Madrigal Pharmaceuticals (MDGL) Enterprise Value (2019 - 2025)
Madrigal Pharmaceuticals (MDGL) has disclosed Enterprise Value for 13 consecutive years, with -$203.8 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value fell 94.05% to -$203.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$203.8 million, a 94.05% decrease, with the full-year FY2025 number at -$203.8 million, down 94.05% from a year prior.
- Enterprise Value was -$203.8 million for Q4 2025 at Madrigal Pharmaceuticals, up from -$1.1 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$99.9 million in Q4 2023 to a low of -$1.1 billion in Q3 2025.
- A 5-year average of -$463.9 million and a median of -$303.2 million in 2021 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: skyrocketed 72.15% in 2023, then plummeted 329.79% in 2024.
- Madrigal Pharmaceuticals' Enterprise Value stood at -$270.3 million in 2021, then tumbled by 32.71% to -$358.8 million in 2022, then soared by 72.15% to -$99.9 million in 2023, then decreased by 5.11% to -$105.0 million in 2024, then plummeted by 94.05% to -$203.8 million in 2025.
- Per Business Quant, the three most recent readings for MDGL's Enterprise Value are -$203.8 million (Q4 2025), -$1.1 billion (Q3 2025), and -$797.0 million (Q2 2025).